Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties

Type Publication
Date 2011-04
Language English
Copyright 2011 International Society on Thrombosis and Haemostasis, Wiley-Blackwell
Author(s) Benslimane-Ahmim Z., Heymann D.2, 3, Dizier B., Lokajczyk A.4, Brion R.2, Laurendeau I.5, Bieche I.5, Smadja D. M.4, 6, Galy-Fauroux I.4, Colliec-Jouault SylviaORCID7, Fischer Anne-Marie4, 6, Boisson-Vidal Catherine1
Affiliation(s) 1 : Fac Pharm, INSERM, U765, F-75270 Paris 06, France.
2 : INSERM, UMR S 957, Nantes, France.
3 : Nantes Atlantique Univ, Univ Nantes, Nantes, France.
4 : Univ Paris Cite Paris Descartes, Fac Pharm, Paris, France.
5 : INSERM, U745, Genet Mol Lab, Paris, France.
6 : Hop Europeen Georges Pompidou, AP HP, Dept Haematol, Paris, France.
7 : IFREMER, Nantes, France.
Source Journal Of Thrombosis And Haemostasis (1538-7933) (Wiley-blackwell), 2011-04 , Vol. 9 , N. 4 , P. 834-843
DOI 10.1111/j.1538-7836.2011.04207.x
WOS© Times Cited 25
Keyword(s) endothelial colony-forming cells, osteoprotegerin, receptor activator of nuclear factor-kappa B ligand, vasculogenesis
Abstract Background: Osteoprotegerin (OPG), a soluble receptor of the tumour necrosis factor family, and its ligand, the receptor activator of nuclear factor-kappa B ligand (RANKL), are emerging as important regulators of vascular pathophysiology. Objectives: We evaluated their effects on vasculogenesis induced by endothelial colony-forming cells (ECFC) and on neovessel formation in vivo. Methods: Effects of OPG and RANKL on in vitro angiogenesis were evaluated after ECFC incubation with OPG or RANKL (0-50 ng mL(-1)). Effects on microvessel formation were evaluated with an in vivo murin Matrigel plug assay. Vascularization was evaluated by measuring plug hemoglobin and vascular endothelial growth factor (VEGF)-R2 content 14 days after implantation. Results: We found that ECFC expressed OPG and RANK but not RANKL mRNA. Treatment of ECFC with VEGF or stromal cell-derived factor-1 (SDF-1) upregulated OPG mRNA expression. OPG stimulated ECFC migration (P < 0.05), chemotaxis (P < 0.05) and vascular cord formation on Matrigel (R) (P < 0.01). These effects were correlated with SDF-1 mRNA overexpression, which was 30-fold higher after 4 h of OPG stimulation (P < 0.01). OPG-mediated angiogenesis involved the MAPK signaling pathway as well as Akt or mTOR cascades. RANKL also showed pro-vasculogenic effects in vitro. OPG combined with FGF-2 promoted neovessel formation in vivo, whereas RANKL had no effect. Conclusions: OPG induces ECFC activation and is a positive regulator of microvessel formation in vivo. Our results suggest that the OPG/RANK/RANKL axis may be involved in vasculogenesis and strongly support a modulatory role in tissue revascularization.
Full Text
File Pages Size Access
10 499 KB Access on demand
Author's final draft 27 427 KB Open access
Top of the page

How to cite 

Benslimane-Ahmim Z., Heymann D., Dizier B., Lokajczyk A., Brion R., Laurendeau I., Bieche I., Smadja D. M., Galy-Fauroux I., Colliec-Jouault Sylvia, Fischer Anne-Marie, Boisson-Vidal Catherine (2011). Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. Journal Of Thrombosis And Haemostasis, 9(4), 834-843. Publisher's official version : https://doi.org/10.1111/j.1538-7836.2011.04207.x , Open Access version : https://archimer.ifremer.fr/doc/00033/14462/